Extracellular Vesicle Therapy for Type 1 Diabetes

Type 1 diabetes (T1D) is a chronic disorder characterized by immune-mediated destruction of pancreatic insulin-producing β-cells. The primary treatment for T1D is multiple daily insulin injections to control blood sugar levels. Cell-free delivery packets with therapeutic properties, extracellular ve...

Descripción completa

Detalles Bibliográficos
Autores principales: Soltani, Setareh, Mansouri, Kamran, Emami Aleagha, Mohammad Sajad, Moasefi, Narges, Yavari, Niloofar, Shakouri, Seyed Kazem, Notararigo, Sara, Shojaeian, Ali, Pociot, Flemming, Yarani, Reza
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9024141/
https://www.ncbi.nlm.nih.gov/pubmed/35464488
http://dx.doi.org/10.3389/fimmu.2022.865782
_version_ 1784690505262563328
author Soltani, Setareh
Mansouri, Kamran
Emami Aleagha, Mohammad Sajad
Moasefi, Narges
Yavari, Niloofar
Shakouri, Seyed Kazem
Notararigo, Sara
Shojaeian, Ali
Pociot, Flemming
Yarani, Reza
author_facet Soltani, Setareh
Mansouri, Kamran
Emami Aleagha, Mohammad Sajad
Moasefi, Narges
Yavari, Niloofar
Shakouri, Seyed Kazem
Notararigo, Sara
Shojaeian, Ali
Pociot, Flemming
Yarani, Reza
author_sort Soltani, Setareh
collection PubMed
description Type 1 diabetes (T1D) is a chronic disorder characterized by immune-mediated destruction of pancreatic insulin-producing β-cells. The primary treatment for T1D is multiple daily insulin injections to control blood sugar levels. Cell-free delivery packets with therapeutic properties, extracellular vesicles (EVs), mainly from stem cells, have recently gained considerable attention for disease treatments. EVs provide a great potential to treat T1D ascribed to their regenerative, anti-inflammatory, and immunomodulatory effects. Here, we summarize the latest EV applications for T1D treatment and highlight opportunities for further investigation.
format Online
Article
Text
id pubmed-9024141
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-90241412022-04-23 Extracellular Vesicle Therapy for Type 1 Diabetes Soltani, Setareh Mansouri, Kamran Emami Aleagha, Mohammad Sajad Moasefi, Narges Yavari, Niloofar Shakouri, Seyed Kazem Notararigo, Sara Shojaeian, Ali Pociot, Flemming Yarani, Reza Front Immunol Immunology Type 1 diabetes (T1D) is a chronic disorder characterized by immune-mediated destruction of pancreatic insulin-producing β-cells. The primary treatment for T1D is multiple daily insulin injections to control blood sugar levels. Cell-free delivery packets with therapeutic properties, extracellular vesicles (EVs), mainly from stem cells, have recently gained considerable attention for disease treatments. EVs provide a great potential to treat T1D ascribed to their regenerative, anti-inflammatory, and immunomodulatory effects. Here, we summarize the latest EV applications for T1D treatment and highlight opportunities for further investigation. Frontiers Media S.A. 2022-04-08 /pmc/articles/PMC9024141/ /pubmed/35464488 http://dx.doi.org/10.3389/fimmu.2022.865782 Text en Copyright © 2022 Soltani, Mansouri, Emami Aleagha, Moasefi, Yavari, Shakouri, Notararigo, Shojaeian, Pociot and Yarani https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Soltani, Setareh
Mansouri, Kamran
Emami Aleagha, Mohammad Sajad
Moasefi, Narges
Yavari, Niloofar
Shakouri, Seyed Kazem
Notararigo, Sara
Shojaeian, Ali
Pociot, Flemming
Yarani, Reza
Extracellular Vesicle Therapy for Type 1 Diabetes
title Extracellular Vesicle Therapy for Type 1 Diabetes
title_full Extracellular Vesicle Therapy for Type 1 Diabetes
title_fullStr Extracellular Vesicle Therapy for Type 1 Diabetes
title_full_unstemmed Extracellular Vesicle Therapy for Type 1 Diabetes
title_short Extracellular Vesicle Therapy for Type 1 Diabetes
title_sort extracellular vesicle therapy for type 1 diabetes
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9024141/
https://www.ncbi.nlm.nih.gov/pubmed/35464488
http://dx.doi.org/10.3389/fimmu.2022.865782
work_keys_str_mv AT soltanisetareh extracellularvesicletherapyfortype1diabetes
AT mansourikamran extracellularvesicletherapyfortype1diabetes
AT emamialeaghamohammadsajad extracellularvesicletherapyfortype1diabetes
AT moasefinarges extracellularvesicletherapyfortype1diabetes
AT yavariniloofar extracellularvesicletherapyfortype1diabetes
AT shakouriseyedkazem extracellularvesicletherapyfortype1diabetes
AT notararigosara extracellularvesicletherapyfortype1diabetes
AT shojaeianali extracellularvesicletherapyfortype1diabetes
AT pociotflemming extracellularvesicletherapyfortype1diabetes
AT yaranireza extracellularvesicletherapyfortype1diabetes

Ejemplares similares